Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded at Wolfe Research

Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by Wolfe Research to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other research analysts have also recently commented on XENE. Wells Fargo & Company upped their target price on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, December 11th. Royal Bank Of Canada boosted their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $55.17.

Xenon Pharmaceuticals Trading Up 4.8%

Shares of NASDAQ:XENE opened at $44.79 on Monday. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.60. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -11.51 and a beta of 0.96. The firm’s 50-day moving average is $42.45 and its 200 day moving average is $40.89.

Insider Activity at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders sold 65,302 shares of company stock valued at $2,924,128. Insiders own 4.07% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in XENE. Elevation Point Wealth Partners LLC purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at about $32,000. Danske Bank A S bought a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $32,000. Blue Trust Inc. lifted its position in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Xenon Pharmaceuticals during the fourth quarter valued at approximately $33,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.